Chronic Myeloid Leukemia

The race against chronic myeloid leukemia not yet won

Although significant progress has been made in treating chronic myeloid leukemia, the disease cannot yet be eliminated in all patients, and that challenge must be addressed, states a commentary in CMAJ (Canadian Medical Association ...

Jan 23, 2012
popularity0 comments 0

A new approach to fighting chronic myeloid leukemia

Chronic myeloid leukemia develops when a gene mutates and causes an enzyme to become hyperactive, causing blood-forming stem cells in the bone marrow to grow rapidly into abnormal cells. The enzyme, Abl-kinase, is a member ...

Nov 17, 2014
popularity0 comments 0

Leukemia like Achilles, has its own weakness

Leukemia cells from chronic myeloid leukemia patients, especially those in the advanced stage, lack the BRCA1 protein. Importantly, the protein is not present even if the patient carries the proper, unmutated gene responsible ...

Mar 26, 2015
popularity11 comments 0

Study yields new strategy against high-risk leukemia

August 29, 2013) St. Jude Children's Research Hospital scientists have identified a protein that certain high-risk acute lymphoblastic leukemia (ALL) cells need to survive and have used that knowledge to fashion a more effective ...

Aug 29, 2013
popularity0 comments 0

Battling defiant leukemia cells

Two gene alterations pair up to promote the growth of leukemia cells and their escape from anti-cancer drugs, according to a study in The Journal of Experimental Medicine.

Oct 07, 2013
popularity0 comments 0

Chronic myelogenous (or myeloid) leukemia (CML), also known as chronic granulocytic leukemia (CGL), is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes (neutrophils, eosinophils, and basophils) and their precursors is the main finding. It is a type of myeloproliferative disease associated with a characteristic chromosomal translocation called the Philadelphia chromosome. CML is now largely treated with tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, or nilotinib, which have led to dramatically improved survival rates since their introduction in the last decade.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Functional human liver cells grown in the lab

In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. ...

Combination therapy can prevent cytostatic resistance

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

New strategy for treating arthritis discovered

Arthritis patients could one day benefit from a novel form of medicine, according to researchers at Queen Mary University of London (QMUL). Their early study indicates that arthritic cartilage, previously thought to be impenetrable ...